Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked…
Overview of attention for article published in Journal of Clinical Oncology, August 2009
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (88th percentile)
-
Good Attention Score compared to outputs of the same age and source (72nd percentile)
Mentioned by
- policy
- 1 policy source
- patent
- 1 patent
- f1000
- 1 research highlight platform
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 78 Mendeley